TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 321863

Group type: EXPERIMENTAL
Intervention: Berberin drops
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 12
Study: 30327158

Group type: EXPERIMENTAL
Intervention: Spinal immobilization at 20°
Number of subjects: 140

Group type: COMPARATOR
Intervention: Spinal immobilization at 0°
Number of subjects: 140
Study: 26951795

Group type: EXPERIMENTAL
Intervention: Difficult patients (distressing behaviours)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Neutral patients
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Deliberate reflection on cases
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Difficult patients
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Difficult and neutral patients
Number of subjects: 63
Study: 26195056

Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a every 2 weeks
Number of subjects: 1012

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1012
Study: 24196331

Group type: EXPERIMENTAL
Intervention: Laser therapy (1319 nm, 1064 nm, and BroadBand Light)
Number of subjects: 21
Study: 21530095

Group type: EXPERIMENTAL
Intervention: 75 mg of zinc sulfate orally in water daily for 6 weeks + one capsule of vitamin B-complex + one capsule of vitamin A or E (first 10 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Proposed placebo-controlled trials with incremental doses of zinc sulfate along with magnesium and selenium
Number of subjects: 30
Study: 18505442

Group type: EXPERIMENTAL
Intervention: Iopanoic acid (IA) 3 g/day for 7 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carbimazole 30 mg/day for 1 month
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (7 normal women)
Number of subjects: 14
Study: 16920374

Group type: EXPERIMENTAL
Intervention: Betamethasone (Group I)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Betamethasone (Group II)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Preterm controls (Group III)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Term controls (Group IV)
Number of subjects: 4
Study: 12573307

Group type: EXPERIMENTAL
Intervention: Platelet [(3)H]paroxetine binding sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promoter polymorphism (short deletion variant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allele or genotype frequency for the three polymorphisms
Number of subjects: 0
Study: 11205093

Group type: EXPERIMENTAL
Intervention: Nation-wide multifaceted intervention programme involving general practitioners (GPs)
Number of subjects: 988
Study: 9135951

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic amino acids (L-arginine 2 g/day plus L-lysine 0.5 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8031342

Group type: EXPERIMENTAL
Intervention: morphine (2 mg.ml‐1) with droperidol (0.2 mg.ml‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: morphine alone (2 mg.ml‐1)
Number of subjects: 60
Study: 3003445

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HTZ) administration, 25 mg 12-hrly for 18 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control days (no HTZ)
Number of subjects: 6
Study: 31375620

Group type: EXPERIMENTAL
Intervention: 12-week muscle strengthening exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 29079460

Group type: EXPERIMENTAL
Intervention: tACS frequency group A (above IGF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: tACS frequency group B (below IGF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 26
Study: 27875286

Group type: EXPERIMENTAL
Intervention: Immunomodulatory formula (IF) 400 mL/d for 10 days prior to surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Commonly used formula (CF)
Number of subjects: 38
Study: 24759901

Group type: EXPERIMENTAL
Intervention: Vicarious group-based rejection (observing rejection of ingroup members)
Number of subjects: 0
Study: 22357739

Group type: EXPERIMENTAL
Intervention: Consumption of vitamin D and calcium-fortified soft white cheese (2 servings of 100 g daily for 6 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Not consuming the fortified cheese (control group)
Number of subjects: 71
Study: 20532660

Group type: EXPERIMENTAL
Intervention: Educational intervention about Medicare's 'no pay for errors' rule
Number of subjects: 168

Group type: COMPARATOR
Intervention: No information provided (control group)
Number of subjects: 168
Study: 19037467

Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 0
Study: 16320709

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dextran treatment
Number of subjects: 100
Study: 12923655

Group type: EXPERIMENTAL
Intervention: Concentrated bovine colostrum protein (CBC) 60g/day for 8 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Whey protein (WP) for 8 weeks
Number of subjects: 174
Study: 10586393

Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous infusion (18 min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 2 mg/kg oral solution
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 150 mg orally administered capsule
Number of subjects: 27
Study: 8767364

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: New guidelines for thrombolytic therapy
Number of subjects: 1328
Study: 1841935

Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) 60 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-treatment (NT)
Number of subjects: 30
Study: 6350402

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (150, 300, or 600 IU/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 31759877

Group type: EXPERIMENTAL
Intervention: Teres major transfer to the infraspinatus tendon
Number of subjects: 20
Study: 30121734

Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28724862

Group type: EXPERIMENTAL
Intervention: Electrosurgery (ES group, 25 teeth)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional method (C group, 25 teeth)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electrosurgery (ES group)
Number of subjects: 50
Study: 26414022

Group type: EXPERIMENTAL
Intervention: Avagacestat (50 mg/d)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Avagacestat (125 mg/d)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Avagacestat
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263

Group type: COMPARATOR
Intervention: Avagacestat vs Placebo
Number of subjects: 263
Study: 23617621

Group type: EXPERIMENTAL
Intervention: Modified treatment (ModTx)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard treatment (StTx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21543538

Group type: COMPARATOR
Intervention: Controlled research meals with lower protein intake (0.9-1.1 g protein · kg(‐1) · d(‐1) reduced by 0.2 to 0.3 g · kg(‐1) · d(‐1))
Number of subjects: 112

Group type: COMPARATOR
Intervention: Controlled research meals with higher protein intake (0.9-1.1 g protein · kg(‐1) · d(‐1) increased by 0.2 g · kg(‐1) · d(‐1))
Number of subjects: 112
Study: 19056566

Group type: EXPERIMENTAL
Intervention: Monosodium L-glutamate (MSG) added to a protein-rich liquid meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Monosodium L-glutamate (MSG) added to a carbohydrate meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Monosodium L-glutamate (MSG) added to noncaloric water
Number of subjects: 10
Study: 16400050

Group type: EXPERIMENTAL
Intervention: Low-phytate maize
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isohybrid wild-type maize
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local maize
Number of subjects: 60
Study: 14722705

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11407289

Group type: EXPERIMENTAL
Intervention: Ketamine 1.5 mg/kg i.v.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiamylal 5 mg/kg i.v.
Number of subjects: 40
Study: 9427902

Group type: EXPERIMENTAL
Intervention: Continuous phenobarbital therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intermittent diazepam
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pyridoxine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 9
Study: 7959558

Group type: EXPERIMENTAL
Intervention: Roux-en-Y anastomosis
Number of subjects: 94

Group type: COMPARATOR
Intervention: Billroth II anastomosis
Number of subjects: 94
Study: 3559333

Group type: EXPERIMENTAL
Intervention: Regimen I: rifampin 600 mg once a month for 6 months with dapsone 100 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen II: same as Regimen I, supplemented with an additional 6 months' treatment with dapsone 100 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen III: same as Regimen II, with rifampin administered daily for the first 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regimen I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regimen II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regimen III
Number of subjects: 0
Study: 31421394

Group type: EXPERIMENTAL
Intervention: 2.5% GS solution with 15% glucose
Number of subjects: 9

Group type: COMPARATOR
Intervention: 25 mL of water (control) with 15% glucose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2.5% GS solution with 0.09% aspartame
Number of subjects: 9

Group type: COMPARATOR
Intervention: 25 mL of water (control) with 0.09% aspartame
Number of subjects: 9
Study: 28134330

Group type: EXPERIMENTAL
Intervention: Genetically predicted triglyceride levels (C allele of rs662799 variant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetically predicted triglyceride levels
Number of subjects: 0
Study: 25159737

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study: 23124598

Group type: COMPARATOR
Intervention: Peritoneal CUP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Breast CUP
Number of subjects: 40
Study: 21519801

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) hemorrhoidectomy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional diathermy Milligan-Morgan hemorrhoidectomy (MMH)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 210
Study: 18477276

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 20
Study: 17065029

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) for 6 months (6H)
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: Isoniazid plus rifampicin for 3 months (3HR)
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: Isoniazid plus rifampicin plus pyrazinamide for 3 months (3HRZ)
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Placebo for 6 months (PPD-positive)
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Placebo (anergic)
Number of subjects: 2736
Study: 15363053

Group type: EXPERIMENTAL
Intervention: Rapid intravenous iron injection (100 mg of iron sucrose every 2 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Slow intravenous iron infusion (100 mg of iron sucrose every 2 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Rapid intravenous iron injection
Number of subjects: 19

Group type: COMPARATOR
Intervention: Slow intravenous iron infusion
Number of subjects: 19
Study: 11606146

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 250

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 250
Study: 9931784

Group type: EXPERIMENTAL
Intervention: Thyroidectomy and modified radical neck dissection (n = 18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subtotal thyroid resection (n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thyroidectomy (n = 12) partly with selective lymphadenectomy
Number of subjects: 40
Study: 8087930

Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP) infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 11
Study: 2489862

Group type: EXPERIMENTAL
Intervention: Speed condition
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Accuracy condition
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Speed and accuracy condition
Number of subjects: 10
Study: 31265187

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (with PE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy expert (treatment provider)
Number of subjects: 96
Study: 25405570

Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: BZA 20 mg
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/MPA 1.5 mg
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg and CE 0.625 mg/BZA 20 mg
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1843
Study: 23233662

Group type: EXPERIMENTAL
Intervention: Methotrexate (24‐hour infusion of a 1 g/m2 dose or 4‐hour infusion of a 2 g/m2 dose)
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate treatment
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment with 5 different regimens
Number of subjects: 1279
Study: 21534706

Group type: EXPERIMENTAL
Intervention: Conditional event interpretation
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Conjunction interpretation
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Response times for conditional event interpretations
Number of subjects: 131
Study: 19690242

Group type: EXPERIMENTAL
Intervention: Skin-Traction Method (STM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-Skin-Traction Method (non-STM)
Number of subjects: 28
Study: 16968805

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15466104

Group type: EXPERIMENTAL
Intervention: HEDIS criteria for persistent asthma
Number of subjects: 896

Group type: COMPARATOR
Intervention: NHLBI criteria for persistent asthma
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: HEDIS criteria sensitivity
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: HEDIS criteria specificity
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: HEDIS criteria sensitivity for children without daily controller medications
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: HEDIS criteria specificity for children without daily controller medications
Number of subjects: 896
Study: 11303163

Group type: EXPERIMENTAL
Intervention: End-inspiration removal (n = 52)
Number of subjects: 69

Group type: COMPARATOR
Intervention: End-expiration removal (n = 50)
Number of subjects: 69
Study: 9296937

Group type: EXPERIMENTAL
Intervention: Pregnant women with symptoms of threatened abortion (6‐15 weeks)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Women who did not undergo miscarriage
Number of subjects: 128

Group type: COMPARATOR
Intervention: Healthy women in the first trimester of uncomplicated pregnancy (6‐15 weeks)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Healthy not pregnant women
Number of subjects: 128
Study: 8518377

Group type: EXPERIMENTAL
Intervention: Isoflurane-N2O
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 14
Study: 2446275

Group type: EXPERIMENTAL
Intervention: VVI + activity mode pacing (RRP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: RRP
Number of subjects: 15
Study: 30503230

Group type: EXPERIMENTAL
Intervention: Oculus Rift virtual reality assessment in vestibular hypofunction group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oculus Rift virtual reality assessment in control group
Number of subjects: 41
Study: 26956025

Group type: EXPERIMENTAL
Intervention: Exercise (EX) group who walked at 60% VO2peak to expend ≈ 5 kcal/kgbw one hour following the high-fat meal (HFM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (CON) who remained sedentary during the postprandial period
Number of subjects: 39
Study: 26400835

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP) induction dosing patterns
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: BUP induction trajectory bup6
Number of subjects: 740

Group type: COMPARATOR
Intervention: BUP induction trajectory
Number of subjects: 740
Study: 23261733

Group type: COMPARATOR
Intervention: Fluoxetine alone (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoxetine and Cognitive Behavioral Therapy (CBT) (Group B)
Number of subjects: 30
Study: 20518173

Group type: EXPERIMENTAL
Intervention: Heat sensitive moxibustion
Number of subjects: 160

Group type: COMPARATOR
Intervention: Traditional hanging moxibustion
Number of subjects: 160

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 160
Study: 18484250

Group type: EXPERIMENTAL
Intervention: Single leech application (n = 38)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Double leech application (n = 35)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 113
Study: 15930064

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention with special resources for therapy
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention with special resources for medication management
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1356
Study: 14595996

Group type: EXPERIMENTAL
Intervention: T'ai Chi exercise (1-hour sessions, twice weekly for 6 weeks)
Number of subjects: 39
Study: 10793607

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 50 mg administered rectally 30 min before anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 0
Study: 8793254

Group type: EXPERIMENTAL
Intervention: Flurbiprofen LAT (40 mg b.d.)
Number of subjects: 137
Study: 1740600

Group type: EXPERIMENTAL
Intervention: Daily supplement of 560 +/- 16 kcal/day (17% energy from protein, 43% from carbohydrate, 40% from fat) during 12 weeks of resistance training.
Number of subjects: 11

Group type: COMPARATOR
Intervention: No supplement during 12 weeks of resistance training.
Number of subjects: 11
Study: 6442383

Group type: EXPERIMENTAL
Intervention: Oxazepam (OX) 45 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diazepam (D) 15 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nordiazepam (ND) 15 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diazepam (D) 5 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oxazepam (OX) 15 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nordiazepam (ND) 5 mg
Number of subjects: 7
Study: 30418528

Group type: EXPERIMENTAL
Intervention: HIV/Immed-ART-12
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: HIV/Immed-ART-24
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: HIV/Def-ART
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: HEU
Number of subjects: 311
Study: 30114796

Group type: EXPERIMENTAL
Intervention: Randomized grating condenser zone plate (GCZP)
Number of subjects: 0
Study: 27075905

Group type: EXPERIMENTAL
Intervention: Vitamin B-12 intake of 1.5 μg/d (0.3, 9.7 μg/d); 60% consumed <2.4 μg/d.
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Household Hunger Scale measurement indicated moderate or severe hunger prevalence of 27%.
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Animal-source food score ranged from 0 to 30 item-d/wk.
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Maternal age as a variable.
Number of subjects: 286
Study: 24593269

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 22313988

Group type: EXPERIMENTAL
Intervention: Primer/Vitremer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond/Durafill VS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond/Z100
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 20668330

Group type: EXPERIMENTAL
Intervention: Topical cyanoacrylates applied every 3‐5 days for 3 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Topical silicone gel applied twice a day for 3 months
Number of subjects: 150
Study: 17603862

Group type: EXPERIMENTAL
Intervention: 904 Ga‐As laser CW, frequency 50 Hz, intensity 40 mW, energy density 2.4 J/cm(2) plus plyometric exercises
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo laser plus plyometric exercises
Number of subjects: 50
Study: 16123686

Group type: EXPERIMENTAL
Intervention: Condom promotion program teaching technical use skills in workshops
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control group received a brief informational presentation about AIDS
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Condom promotion program
Number of subjects: 498
Study: 12049706

Group type: EXPERIMENTAL
Intervention: Low fat but high complex carbohydrates diet (HCO)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (monounsaturated fat-enriched)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saturated fat-enriched (SAT) diet
Number of subjects: 72
Study: 11281499

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol 2 mg and norethisterone acetate 1 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60